CARECLOUD INC (CCLD) Stock Fundamental Analysis
NASDAQ:CCLD - Nasdaq - US14167R1005 - Common Stock - Currency: USD
We assign a fundamental rating of 5 out of 10 to CCLD. CCLD was compared to 37 industry peers in the Health Care Technology industry. Both the profitability and the financial health of CCLD get a neutral evaluation. Nothing too spectacular is happening here. CCLD is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
CCLD had negative earnings in the past year.
CCLD had a positive operating cash flow in the past year.
In the past 5 years CCLD always reported negative net income.
Of the past 5 years CCLD 4 years had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -5.12%, CCLD belongs to the best of the industry, outperforming 81.08% of the companies in the same industry.
CCLD has a Return On Equity of -6.96%. This is amongst the best in the industry. CCLD outperforms 81.08% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.91%, CCLD belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.12% | ||
| ROE | -6.96% | ||
| ROIC | 15.91% |
ROA(3y)-32.11%
ROA(5y)-24.15%
ROE(3y)-57.71%
ROE(5y)-41.4%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of CCLD (10.13%) is better than 89.19% of its industry peers.
CCLD's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 45.67%, CCLD is doing worse than 62.16% of the companies in the same industry.
CCLD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.13% | ||
| PM (TTM) | N/A | ||
| GM | 45.67% |
OM growth 3Y59.79%
OM growth 5Y95.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.11%
GM growth 5Y4.51%
2. Health
2.1 Basic Checks
CCLD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for CCLD has been increased compared to 1 year ago.
Compared to 5 years ago, CCLD has more shares outstanding
The debt/assets ratio for CCLD has been reduced compared to a year ago.
2.2 Solvency
CCLD has an Altman-Z score of 3.65. This indicates that CCLD is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.65, CCLD is doing good in the industry, outperforming 78.38% of the companies in the same industry.
CCLD has a debt to FCF ratio of 0.01. This is a very positive value and a sign of high solvency as it would only need 0.01 years to pay back of all of its debts.
The Debt to FCF ratio of CCLD (0.01) is better than 86.49% of its industry peers.
CCLD has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CCLD (0.00) is better than 70.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 3.65 |
ROIC/WACC1.44
WACC11.06%
2.3 Liquidity
A Current Ratio of 1.69 indicates that CCLD should not have too much problems paying its short term obligations.
CCLD has a Current ratio (1.69) which is comparable to the rest of the industry.
A Quick Ratio of 1.65 indicates that CCLD should not have too much problems paying its short term obligations.
CCLD has a Quick ratio (1.65) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.65 |
3. Growth
3.1 Past
CCLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.03%, which is quite impressive.
The Revenue has decreased by -0.45% in the past year.
The Revenue has been growing by 11.47% on average over the past years. This is quite good.
EPS 1Y (TTM)81.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-0.45%
Revenue growth 3Y-7.4%
Revenue growth 5Y11.47%
Sales Q2Q%6.43%
3.2 Future
The Earnings Per Share is expected to grow by 67.81% on average over the next years. This is a very strong growth
CCLD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.18% yearly.
EPS Next Y151%
EPS Next 2Y67.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.95%
Revenue Next 2Y4.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CCLD. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 12.38, the valuation of CCLD can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CCLD indicates a rather cheap valuation: CCLD is cheaper than 91.89% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CCLD to the average of the S&P500 Index (22.15), we can say CCLD is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.38 |
4.2 Price Multiples
100.00% of the companies in the same industry are more expensive than CCLD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CCLD is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.82 | ||
| EV/EBITDA | 3.12 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CCLD's earnings are expected to grow with 67.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.81%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CCLD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.02
-0.1 (-4.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners11.24%
Inst Owner ChangeN/A
Ins Owners37.42%
Ins Owner Change6.3%
Market Cap85.49M
Analysts82
Price Target4.25 (110.4%)
Short Float %1.61%
Short Ratio0.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.92
Dividend Growth(5Y)21.2%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.78%
Min EPS beat(2)21.57%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)-41.12%
Min EPS beat(4)-357.52%
Max EPS beat(4)100%
EPS beat(8)4
Avg EPS beat(8)-16.18%
EPS beat(12)8
Avg EPS beat(12)-4.32%
EPS beat(16)12
Avg EPS beat(16)5.81%
Revenue beat(2)1
Avg Revenue beat(2)2.25%
Min Revenue beat(2)-1.1%
Max Revenue beat(2)5.6%
Revenue beat(4)1
Avg Revenue beat(4)0.16%
Min Revenue beat(4)-1.99%
Max Revenue beat(4)5.6%
Revenue beat(8)1
Avg Revenue beat(8)-3.14%
Revenue beat(12)1
Avg Revenue beat(12)-3.28%
Revenue beat(16)4
Avg Revenue beat(16)-1.86%
PT rev (1m)-1.96%
PT rev (3m)-20.48%
EPS NQ rev (1m)-60%
EPS NQ rev (3m)142.1%
EPS NY rev (1m)-11.76%
EPS NY rev (3m)148.54%
Revenue NQ rev (1m)-4.88%
Revenue NQ rev (3m)-3.71%
Revenue NY rev (1m)-0.43%
Revenue NY rev (3m)-0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.38 | ||
| P/S | 0.76 | ||
| P/FCF | 5.82 | ||
| P/OCF | 3.94 | ||
| P/B | 1.58 | ||
| P/tB | 4.72 | ||
| EV/EBITDA | 3.12 |
EPS(TTM)-0.22
EYN/A
EPS(NY)0.16
Fwd EY8.08%
FCF(TTM)0.35
FCFY17.17%
OCF(TTM)0.51
OCFY25.37%
SpS2.66
BVpS1.28
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.12% | ||
| ROE | -6.96% | ||
| ROCE | 20.14% | ||
| ROIC | 15.91% | ||
| ROICexc | 18.08% | ||
| ROICexgc | 65.54% | ||
| OM | 10.13% | ||
| PM (TTM) | N/A | ||
| GM | 45.67% | ||
| FCFM | 13.05% |
ROA(3y)-32.11%
ROA(5y)-24.15%
ROE(3y)-57.71%
ROE(5y)-41.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y52.71%
ROICexcg growth 5Y104.32%
ROICexc growth 3Y91.65%
ROICexc growth 5Y92.03%
OM growth 3Y59.79%
OM growth 5Y95.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.11%
GM growth 5Y4.51%
F-Score7
Asset Turnover1.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 50.58% | ||
| Cap/Sales | 6.23% | ||
| Interest Coverage | 28.5 | ||
| Cash Conversion | 85.88% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.65 | ||
| Altman-Z | 3.65 |
F-Score7
WACC11.06%
ROIC/WACC1.44
Cap/Depr(3y)74.91%
Cap/Depr(5y)76.9%
Cap/Sales(3y)8.36%
Cap/Sales(5y)8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y151%
EPS Next 2Y67.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.45%
Revenue growth 3Y-7.4%
Revenue growth 5Y11.47%
Sales Q2Q%6.43%
Revenue Next Year0.95%
Revenue Next 2Y4.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y416.02%
EBIT growth 3Y47.96%
EBIT growth 5Y117.42%
EBIT Next Year208.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y107.65%
FCF growth 3Y68.43%
FCF growth 5Y21.21%
OCF growth 1Y13.67%
OCF growth 3Y15.69%
OCF growth 5Y22.06%